P2-033Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Dose Dense in Stage III Breast Cancer

Annals of Oncology - United Kingdom
doi 10.1093/annonc/mdy375.034
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Feasibility Study of Bevacizumab Plus Dose-Dense Doxorubicin-Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2011English

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Fifteen-Year Median Follow-Up Results After Neoadjuvant Doxorubicin, Followed by Mastectomy, Followed by Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Followed by Radiation for Stage III Breast Cancer: A Phase II Trial (CALGB 8944)

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

High Dose, Dose-Intensive Chemotherapy With Doxorubicin and Cyclophosphamide for the Treatment of Advanced Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
1993English

Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (Registration Number: ChiCTR1900023052)

Scientific Reports
Multidisciplinary
2019English

Epirubicin/Cyclophosphamide Followed by Docetaxel as Primary Systemic Therapy in Breast Cancer

Annals of Cancer Research and Therapy
Cancer ResearchOncologyPharmacology
2014English

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-Negative HER2-Overexpressed Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Pharmacogenetics of Toxicity of 5-Fluorouracil, Doxorubicin and Cyclophosphamide Chemotherapy in Breast Cancer Patients

Oncotarget
Oncology
2018English

Neoadjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide Chemotherapy Followed by Docetaxel in Refractory Patients With Locally Advanced Breast Cancer

Oncology Reports
MedicineCancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy